Recent advances on stearoyl-CoA desaturase regulation in fatty liver diseases

Current Drug Metabolism

Volumn 13, Issue 10, 2012, Pages 1454-1463

  Narce, Michel ^a   Bellenger, Jérôme ^a   Rialland, Mickaël ^a   Bellenger, Sandrine ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Alcoholic steatohepatitis; Fatty acids; Inflammation; Nonalcoholic steatohepatitis; Obesity metabolic syndrome; Stearoyl CoA desaturase

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACYL COENZYME A DESATURASE 1; ALANINE AMINOTRANSFERASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; CCAAT BINDING FACTOR; CD36 ANTIGEN; CONJUGATED LINOLEIC ACID; FAS ANTIGEN; FATTY ACID; INSULIN; INTERLEUKIN 1; LEPTIN; LIVER X RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OMEGA 3 FATTY ACID; OXYGENASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PREGNANE X RECEPTOR; ROSIGLITAZONE; SATURATED FATTY ACID; SIRTUIN 1; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STROMELYSIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLIC FATTY LIVER; BODY FAT DISTRIBUTION; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; ENERGY EXPENDITURE; ENZYME INHIBITION; ENZYME REGULATION; FAT INTAKE; FATTY LIVER; GENE EXPRESSION; GENETIC VARIABILITY; GLUCOSE TOLERANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID COMPOSITION; LIPID METABOLISM; LIPID OXIDATION; LIPID STORAGE; LIPOGENESIS; LIPOTOXICITY; LIVER CELL; MACROPHAGE; METABOLIC SYNDROME X; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; REVIEW; STEATOSIS; ZUCKER RAT;

ANIMALS; FATTY ACIDS, UNSATURATED; FATTY LIVER; FATTY LIVER, ALCOHOLIC; HUMANS; STEAROYL-COA DESATURASE; TRANSCRIPTION FACTORS;

EID: 84870472400     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012803762693     Document Type: Review

References (102)

1. Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Human fatty liver disease: old questions and new insights. Science, 2011, 332, 1519-23.
2. Vernon, G.; Baranova, A.; Younossi, Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther., 2011, 34, 274-85.
3. Perseghin, G. Lipids in the wrong place: visceral fat and nonalcoholicsteatohepatitis. Diabetes Care, 2011,34 Suppl 2, S367-70.
4. Harmon, R.C.; Tiniakos, D.G.; Argo, C.K. Inflammation in nonalcoholic steatohepatitis. Expert. Rev. Gastroenterol. Hepatol, 2011, 5, 189-200.
5. Aly, F.Z.; Kleiner, D.E. Update on fatty liver disease and steatohepatitis. Adv. Anat. Pathol., 2011, 18, 294-300.
6. Day, C.P. Non-alcoholic fatty liver disease: a massive problem. Clin. Med., 2011, 11, 176-8.
7. Ibrahim, S.H.; Kohli, R.; Gores, G.J. Mechanisms of Lipotoxicity in NAFLD and Clinical Implications. J. Pediatr. Gastroenterol. Nutr., 2011, 53, 131-40.
8. Bataller, R.; Rombouts, K.; Altamirano, J.; Marra, F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin. Gastroenterol., 2011, 25, 231-244.
9. Sozio, M.; Crabb, D.W. Alcohol and lipid metabolism. Am. J. Physiol. Endocrinol. Metab., 2008, 295, E10-6.
10. Mills, S.J.; Harrison, S.A. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr. Gastroenterol. Rep., 2005, 7, 32-6.
11. Miranda-Mendez, A.; Lugo-Baruqui, A.; Armendariz-Borunda, J. Molecular basis and current treatment for alcoholic liver disease. Int. J. Environ. Res. Public Health, 2010, 7, 1872-88.
12. Albano, E. New concepts in the pathogenesis of alcoholic liver disease. Expert Rev. Gastroenterol. Hepatol., 2008, 2, 749-59.
13. Cohen, P.; Miyazaki, M.; Socci, N.D.; Hagge-Greenberg, A.; Liedtke, W.; Soukas, A.A.; Sharma, R.; Hudgins, L.C.; Ntambi, J.M.; Friedman, J.M. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science, 2002, 297, 240-243.
14. Bjermo, H.; Riserus, U. Role of hepatic desaturases in obesity-related metabolic disorders. Curr. Opin. Clin. Nutr. Metab. Care, 2010, 13, 703-708.
15. Buque, X.; Martinez, M. J.; Cano, A.; Miquilena-Colina, M.E.; García-Monzón, C.; Aspichueta, P.; Ochoa, B. A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. J. Lipid Res., 2010, 51, 500-513.
16. Biddinger, S. B.; Almind, K.; Miyazaki, M.; Kokkotou, E.; Ntambi, J.M.; Kahn, C.R. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes, 2005 54, 1314-1323.
17. Xie, Z.; Li. H.; Wang, K.; Lin, J.; Wang, Q.; Zhao, G.; Jia, W.; Zhang, Q. Analysis of transcriptome and metabolome profiles alterations in fatty liver induced by high-fat diet in rat. Metabolism, 2010, 59, 554-560.
18. Linden, D.; William-Olsson, L.; Ahnmark, A.; Ekroos, K.; Hallberg, C.; Sjögren, H.P.; Becker, B.; Svensson, L.; Clapham, J.C.; Oscarsson, J.; Schreyer, S. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J., 2006, 20, 434-443.
19. Fevre, C.; Bellenger, S.; Pierre, A.S.; Minville, M.; Bellenger, J.; Gresti, J.; Rialland, M.; Narce, M.; Tessier, C. The metabolic cascade leading to eicosanoid precursors-desaturases, elongases, and phospholipases A2-is altered in Zucker fatty rats. Biochim. Biophys. Acta., 2011, 1811, 409-417.
20. Issandou, M.; Bouillot; A.; Brusq. J.M.; Forest. M.C.; Grillot, D.; Guillard, R.; Martin, S.; Michiels, C.; Sulpice, T.; Daugan, A.Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models. Eur. J. Pharmacol., 2009, 618, 28-36.
21. de Meijer, V. E.; Le, H.D.; Meisel, J.A.; Akhavan, S.M.R.; Pan, A.; Nosé, V.; Puder, M. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism, 2010, 59, 1092-1105.
22. Chanussot, B.; Narce, M.; Poisson, J.P. Liver microsomal delta 6 and delta 5 linoleic acid desaturation in female BB rats. Diabetologia, 1989, 32,786-91.
23. Fukuchi, S.K.; Hamaguchi, K.; Seike, M.; Himeno, K.; Sakata, T.; Yoshimatsu, H. Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats. Exp. Biol. Med., 2004, 229, 486-493.
24. Haque, J. A.; McMahan, R.S.; Campbell, J.S.; Shimizu-Albergine, M.; Wilson, A.M.; Botta, D.; Bammler, T.K.; Beyer, R.P.; Montine, T.J.; Yeh, M.M.; Kavanagh, T.J.; Fausto, N. Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Lab. Invest., 2010, 90, 1704-1717.
25. Cohen, P.; Friedman, J. M. "Leptin and the control of metabolism: role for stearoyl-CoA desaturase-1 (SCD-1). J. Nutr., 2004, 134, 2455S-2463S.
26. Biddinger, S. B.; Miyazaki, M.; Boucher, J.; Ntambi, J.M.; Kahn, C.R.Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c. Diabetes, 2006, 55, 2032-2041.
27. Mauvoisin, D.; Prévost, M.; Ducheix, S.; Arnaud, M.P.; Mounier, C.Key role of the ERK1/2 MAPK pathway in the transcriptional regulation of the Stearoyl-CoA Desaturase (SCD1) gene expression in response to leptin. Mol. Cell. Endocrinol., 2010, 319, 116-128.
28. Ntambi, J. M.; Miyazaki, M.; Stoehr, J.P.; Lan, H.; Kendziorski, C.M.; Yandell, B.S.; Song, Y.; Cohen, P.; Friedman, J.M.; Attie, A.D. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl. Acad. Sci. U. S. A., 2002, 99, 11482-11486.
29. MacDonald, M. L.; Singaraja, R.R.; Bissada, N.; Ruddle, P.; Watts, R.; Karasinska, J.M.; Gibson, W.T.; Fievet, C.; Vance, J.E.; Staels, B.; Hayden, M.R Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. J. Lipid Res., 2008, 49, 217-229.
30. Dobrzyn, P.; Dobrzyn, A.; Miyazaki, M.; Ntambi, J.M. Loss of stearoyl-CoA desaturase 1 rescues cardiac function in obese leptin-deficient mice. J. Lipid Res., 2010, 51, 2202-2210.
31. Brown, J. M.; Chung, S.; Sawyer, J.K.; Degirolamo, C.; Alger, H.M.; Nguyen, T.; Zhu, X.; Duong, M.N.; Wibley, A.L.; Shah, R.; Davis, M.A.; Kelley, K.; Wilson, M.D.; Kent, C.; Parks, J.S.; Rudel, L.L. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation, 2008, 118, 1467-1475.
32. Flowers, M. T. Ntambi, J. M. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr. Opin. Lipidol., 2008, 19, 248-256.
33. Jiang, G.; Li, Z. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J. Clin. Invest., 2005,115, 1030-1038.
34. Gutierrez-Juarez, R.; Pocai. A.; Mulas, C.; Ono, H.; Bhanot, S.; Monia, B.P.; Rossetti, L. Critical role of stearoyl-CoA desaturase-1 (SCD-1) in the onset of diet-induced hepatic insulin resistance. J. Clin. Invest., 2006, 116, 1686-1695.
35. Yokozawa, J., Sasaki. T.; Ohwada, K.; Sasaki, Y.; Ito, J.I.; Saito, T.; Kawata, S. Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis. J. Gastroenterol., 2009, 44, 583-591.
36. Park, H. J.; DiNatale, D.A.; Chung, M.Y.; Park, Y.K.; Lee, J.Y.; Koo, S.I.; O'Connor, M.; Manautou, J.E.; Bruno, R.S. Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J. Nutr. Biochem., 2011, 22, 393-400.
37. Li, Z.Z.; Berk, M.; McIntyre, T.M.; Feldstein, A.E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem., 2009, 284, 5637-5644.
38. Peter, A.; Weigert, C.; Staiger, H.; Machicao, F.; Schick, F.; Machann, J.; Stefan, N.; Thamer, C.; Häring, H.U.; Schleicher, E. Individual stearoyl-coa desaturase 1 expression modulates endoplasmic reticulum stress and inflammation in human myotubes and is associated with skeletal muscle lipid storage and insulin sensitivity in vivo. Diabetes, 2009, 58, 1757-1765.
39. Vessby, B.; Gustafsson, I.B.; Tengblad, S.; Boberg, M.; Andersson, A.Desaturation and elongation of Fatty acids and insulin action. Ann. N. Y. Acad. Sci., 2002, 967, 183-195.
40. Warensjö, E.; Risérus, U.; Gustafsson, .IB.; Mohsen, R.; Cederholm, T.; Vessby, B. Effects of saturated and unsaturated fatty acids on estimated desaturase activities during a controlled dietary intervention. Nutr. Metab. Cardiovasc. Dis., 2008, 18, 683-690.
41. Kotronen, A.; Westerbacka, J.; Bergholm, R.; Pietiläinen, K.H.; Yki-Järvinen, H. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab., 2007, 92, 3490-3497.
42. Kotronen, A.; Seppänen-Laakso, T.; Westerbacka, J.; Kiviluoto, T.; Arola, J.; Ruskeepää, A.L.; Oresic, M.; Yki-Järvinen, H. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes, 2009, 58, 203-208.
43. Warensjo, E.; Risérus, U.; Vessby, B. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia, 2005, 48, 1999-2005.
44. Warensjo, E.; Ohrvall, M.; Vessby. B. Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women. Nutr. Metab. Cardiovasc. Dis., 2006, 16, 128-136.
45. Zhou, Y. E.; Egeland, G.M.; Meltzer, S.J.; Kubow, S. The association of desaturase 9 and plasma fatty acid composition with insulin resistance- associated factors in female adolescents. Metabolism, 2009, 58, 158-166.
46. Riserus, U.; Arnlöv, J.; Berglund, L. Long-term predictors of insulin resistance: role of lifestyle and metabolic factors in middle-aged men. Diabetes Care, 2007, 30, 2928-2933.
47. Corpeleijn, E.; Feskens, E.J.; Jansen, E.H.; Mensink, M.; Saris, W.H.; de Bruin, T.W.; Blaak, E.E. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia, 2006, 49, 2392-2401.
48. Warensjo, E.; Ingelsson, E.; Lundmark, P.; Lannfelt, L.; Syvänen, A.C.; Vessby, B.; Risérus, U. Polymorphisms in the SCD-1 gene: associations with body fat distribution and insulin sensitivity. Obesity, 2007, 15, 1732-1740.
49. Guillen, N.; Navarro, M.A.; Arnal, C.; Noone, E.; Arbonés-Mainar, J.M.; Acín, S.; Surra, J.C.; Muniesa, P.; Roche, H.M.; Osada, J. Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. Physiol. Genomics, 2009, 37, 187-198.
50. Pravenec, M.; Kazdova, L.; Landa, V.; Zidek, V.; Mlejnek, P.; Simakova, M.; Jansa, P.; Forejt, J.; Kren, V.; Krenova, D.; Qi, N.; Wang, J.M.; Chan, D.; Aitman, T.J.; Kurtz, T.W. Identification of mutated Srebf1 as a QTL influencing risk for hepatic steatosis in the spontaneously hypertensive rat. Hypertension, 2008, 51, 148-153.
51. Na, T.Y.; Shin, Y.K.; Roh, K.J.; Kang, S.A.; Hong, I.; Oh, S.J.; Seong, J.K.; Park, C.K.; Choi, Y.L.; Lee, M.O. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology, 2009, 49, 1122-1131.
52. Sekiya, M.; Yahagi, N.; Matsuzaka, T.; Najima, Y.; Nakakuki, M.; Nagai, R.; Ishibashi, S.; Osuga, J.; Yamada, N.; Shimano, H. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology, 2003, 38, 1529-1539.
53. Levy, J. R.; Clore, J.N.; Stevens, W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology, 2004, 39, 608-616.
54. Hagve, T.A.; Woldseth, B; Brox, J.; Narce, M.; Poisson, J.P. Membrane fluidity and fatty acid metabolism in kidney cells from rats fed purified eicosapentaenoic acid or purified docosahexaenoic acid. Scand. J. Clin. Lab. Invest., 1998, 58,187-94.
55. Narce, M.; Frenoux, J.M.; Dardel, V.; Foucher, C.; Germain, S.; Delachambre, M.C.; Poisson, J.P. Fatty acid metabolism, pharmacological nutrients and hypertension. Biochimie, 1997, 79,135-8.
56. Narce, M.; Asdrubal, P.; Delachambre, M.C.; Gresti, J.; Poisson, J.P. Influence of spontaneous hypertension on n-3 delta-6-desaturase activity and fatty acid composition of rat hepatocytes. Mol. Cell. Biochem., 1995, 152, 7-12.
57. Engler, M. M.; Bellenger-Germain, S.H.; Engler, M.B.; Narce, M.M.; Poisson, J.P. Dietary docosahexaenoic acid affects stearic acid desaturation in spontaneously hypertensive rats. Lipids, 2000, 35, 1011-1015.
58. Bellenger, J.; Bellenger, S.; Clément, L.; Mandard, S.; Diot, C.; Poisson, J.P.; Narce, M. A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension. FASEB J., 2004, 18, 773-775.
59. Brown, J. M.; Sawyer, J.K.; Degirolamo, C.; Alger, H.M.; Nguyen, T.M; Zhu, X.; Duong, M.N.; Brown, A.L.; Lord, C.; Shah, R.; Davis, M.A.; Kelley, K.; Wilson, M.D.; Madenspacher, J.; Fessler, M.B.; Parks, J.S.; Rudel, L.L.Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 24-30.
60. Kajikawa, S.; Harada, T.; Kawashima, A.; Imada, K.; Mizuguchi, K. Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 80, 229-238.
61. Purushotham, A.; Shrode, G.E.; Wendel, A.A.; Liu, L.F.; Belury, M A. Conjugated linoleic acid does not reduce body fat but decreases hepatic steatosis in adult Wistar rats. J. Nutr. Biochem., 2007, 18, 676-684
62. Wendel, A. A.; Belury, M. A. Effects of conjugated linoleic acid and troglitazone on lipid accumulation and composition in lean and Zucker diabetic fatty (fa/fa) rats. Lipids, 2006, 41, 241-247.
63. Liu, L. F., Purushotham A, Wendel AA, Belury MA. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292, G1671-1682.
64. Gudbrandsen, O. A.; Wergedahl, H.; Liaset, B.; Espe, M.; Mørk, S.; Berge, R.K. Dietary single cell protein reduces fatty liver in obese Zucker rats. Br. J. Nutr., 2008, 100, 776-785.
65. Tovar, A. R.; Torre-Villalvazo, I.; Ochoa, M.; Elías, A.L.; Ortíz, V.; Aguilar-Salinas, C.A.; Torres, N.Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J. Lipid Res., 2005, 46, 1823-1832.
66. Madani, S.; Prost, J.; Narce, M.; Belleville, J.VLDL metabolism in rats is affected by the concentration and source of dietary protein. J. Nutr., 2003, 133, 4102-4106.
67. Narce, M.; Poisson, J.P.; Belleville, J.; Chanussot, B. Depletion of delta 9 desaturase (EC 1.14.99.5) enzyme activity in growing rat during dietary protein restriction. Br. J. Nutr., 1992, 68, 627-637.
68. Rizki, G. L.; Arnaboldi, L.; Gabrielli, B.; Yan, J.; Lee, G.S.; Ng, R.K.; Turner, S.M.; Badger, T.M.; Pitas, R.E.; Maher, J.J. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J. Lipid Res., 2006, 47, 2280-2290.
69. Comte, C.; Bellenger, S.; Bellenger, J.; Tessier, C.; Poisson, J.P.; Narce, M. Effects of streptozotocin and dietary fructose on delta-6 desaturation in spontaneously hypertensive rat liver. Biochimie, 2004, 86, 799-806.
70. Yamazaki, T.; Shiraishi, S. et al. An increase in liver PPARgamma2 is an initial event to induce fatty liver in response to a diet high in butter: PPARgamma2 knockdown improves fatty liver induced by high-saturated fat. J. Nutr. Biochem., 2011, 22, 543-553.
71. Schroeder-Gloeckler, J. M.; Rahman, S.M.; Janssen, R.C.; Qiao, L.; Shao, J.; Roper, M.; Fischer, S.J.; Lowe, E.; Orlicky, D.J.; McManaman, J.L.; Palmer, C.; Gitomer, W.L.; Huang, W.; O'Doherty, R.M.; Becker, T.C.; Klemm, D.J.; Jensen, D.R.; Pulawa, L.K.; Eckel, R.H.; Friedman, J.E. CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. J. Biol. Chem., 2007, 282, 15717-15729.
72. Basciano, H.; Miller, A.E.; Naples, M.; Baker, C.; Kohen, R.; Xu. E.; Su, Q.; Allister, E.M.; Wheeler, M.B.; Adeli, K. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab., 2009, 297, E462-473.
73. Hwahng, S. H.; Ki, S.H.; Bae, E.J.; Kim, H.E.; Kim, S.G. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology, 2009, 49, 1913-1925.
74. Lee, J. H., Zhou J, Xie W. PXR and LXR in hepatic steatosis, a new dog and an old dog with new tricks. Mol. Pharm., 2008, 5, 60-66.
75. Mitro, N.; Vargas, L.; Romeo, R.; Koder, A.; Saez, E.T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett., 2007, 581, 1721-1726.
76. Li, H.; Meng, Q.; Xiao, F.; Chen, S.; Du, Y.; Yu, J.; Wang, C.; Guo, F. ATF4 deficiency protects mice from high-carbohyd.rate diet-induced liver steatosis. Biochem. J., 2011, 438, 283-289.
77. Dobrzyn, A.; Ntambi, J. M. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes. Rev., 2005, 6, 169-174.
78. Liu, G. Stearoyl-CoA desaturase inhibitors: update on patented compounds. Expert Opin. Ther. Pat., 2009, 19, 1169-1191.
79. Dobrzyn, P.; Dobrzyn, A. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase. Expert Opin. Ther. Pat., 2010, 20, 849-853.
80. Li, J. Z.; Ye, J.; Xue, B.; Qi, J.; Zhang, J.; Zhou, Z.; Li, Q.; Wen, Z.; Li, P.; Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation. Diabetes, 2007, 56, 2523-2532.
81. Serrano, A.; Del Arco, I.; Javier, P.F.; Macías, M.; Perez-Valero, V.; Rodríguez de Fonseca, F. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology, 2008, 54, 226-234.
82. Brown, J. M.; Rudel, L. L. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr. Opin. Lipidol., 2010, 21, 192-197.
83. Shiri-Sverdlov, R.; Wouters, K.; van Gorp, P.J.; Gijbels, M.J.; Noel, B.; Buffat, L.; Staels, B.; Maeda, N.; van Bilsen, M.; Hofker, M.H. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J. Hepatol., 2006, 44, 732-741.
84. Petersson, H.; Basu. S.; Cederholm, T.; Risérus, U. Serum fatty acid composition and indices of stearoyl-CoA desaturase activity are associated with systemic inflammation: longitudinal analyses in middle-aged men. Br. J. Nutr., 2008, 99, 1186-1189.
85. Menghini, R.; Menini, S.; Amoruso, R.; Fiorentino, L.; Casagrande, V.; Marzano, V.; Tornei, F.; Bertucci, P.; Iacobini, C.; Serino, M.; Porzio, O.; Hribal, M.L.; Folli, F.; Khokha, R.; Urbani, A.; Lauro, R.; Pugliese, G.; Federici, M. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology, 2009, 136, 663-672
86. Fessler, M. B.; Rudell L.L.; Brown, J.M. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr. Opin. Lipidol., 2009, 20, 379-385.
87. Chen, C.; Shah, Y.M.; Morimura, K.; Krausz, K.W.; Miyazaki, M.; Richardson, T.A.; Morgan, E.T.; Ntambi, J.M.; Idle, J.R.; Gonzalez, F.J. Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell. Metab., 2008, 7, 135-147.
88. Minville-Walz, M.; Gresti, J.; Pichon, L.; Bellenger, S.; Bellenger, J.; Narce, M.; Rialland, M. Distinct regulation of stearoyl-CoA desaturase 1 gene expression by cis and trans C18:1 fatty acids in human aortic smooth muscle cells. Genes Nutr. 2012, 7, :209-216.
89. Liu, X.; Miyazaki, M.; Flowers, M.T.; Sampath, H.; Zhao, M.; Chu, K.; Paton, C.M.; Joo, D.S.; Ntambi, J.M. Loss of Stearoyl-CoA desaturase-1 attenuates adipocyte inflammation: effects. of adipocyte-derived oleate. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 31-38.
90. Zivkovic, A.; Bruce, M.; German, J.; Esfandiari, F.; Halsted, C.H. Quantitative lipid metabolomic changes in alcoholic micropigs with fatty liver disease. Alcohol. Clin. Exp. Res., 2009, 33, 751-758.
91. Narce, M.; Poisson, J.P.; Bellenger, J.; Bellenger, S. Effect of ethanol on polyunsaturated fatty acid biosynthesis in hepatocytes from spontaneously hypertensive rats. Alcohol. Clin. Exp. Res., 2001, 25, 1231-1237.
92. Tomita, K.; Azuma, T.; Kitamura, N.; Nishida, J.; Tamiya, G.; Oka, A.; Inokuchi, S.; Nishimura, T.; Suematsu, M.; Ishii, H. Pioglitazone prevents alcohol-induced fatty liver in rats through upregulation of c-Met. Gastroenterology, 2004, 126, 873-885.
93. Esfandiari, F.; Villanueva, J.A.; Wong, D.H.; French, S.W.; Halsted, C.H. Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 289, G54-63.
94. You, M.; Fischer, M.; Deeg, M.A.; Crabb, D.W. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J. Biol. Chem., 2002, 277, 29342-29347.
95. Ji, C.; Chan, C.; Kaplowitz, N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J. Hepatol., 2006, 45, 717-724.
96. Yin, H.; Kim, M.; Kim, J.H.; Kong, G.; Kang, K.S.; Kim, H.L.; Yoon, B.I.; Lee, M.O.; Lee, B.H. Differential gene expression and lipid metabolism in fatty liver induced by acute ethanol treatment in mice. Toxicol. Appl. Pharmacol., 2007, 223, 225-233.
97. You, M.; Matsumoto, M.; Pacold, C.M.; Cho, W.K.; Crabb, D.W. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology, 2004,127, 1798-1808.
98. Giandomenico, V.; Simonsson, M.; Grönroos, E.; Ericsson, J. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol., 2003, 23, 2587-2599
99. Toth, J. I.; Datta, S.; Athanikar, J.N.; Freedman, L.P.; Osborne, T.F. Selective coactivator interactions in gene activation by SREBP-1a and -1c. Mol. Cell. Biol., 2004, 24, 8288-8300.
100. You, M.; Liang, X.; Ajmo, J.M.; Ness, G.C. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294, G892-898.
101. You, M.; Cao, Q.; Liang, X.; Ajmo, J.M.; Ness, G.C. Mammalian sirtuin 1 is involved in the protective action of dietary saturated fat against alcoholic fatty liver in mice. J. Nutr., 2008, 138, 497-501.
102. Horiguchi, N.; Wang, L.; Mukhopadhyay, P.; Park, O.; Jeong, W.I.; Lafdil, F.; Osei-Hyiaman, D.; Moh, A.; Fu, X.Y.; Pacher, P.; Kunos, G.; Gao, B. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology, 2008, 134, 1148-1158.